Article
Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission
2026-04-09
Abstract excerpt
<h4>Background: </h4> Chronic myeloid leukemia (CML) is a paradigm of targeted therapy, driven by the BCR::ABL1 fusion kinase. Over the past four decades, therapeutic strategies have evolved from early molecular targeting approaches and interferon-α to tyrosine kinase inhibitors (TKIs), dramatically improving survival and transforming CML into a largely controllable disease. <h4>Methods:</h4> We performed a narrat...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5b6fbbcd-3ddc-5c86-944e-03e43260c932
- DOI
- 10.20944/preprints202604.0598.v1
